Comparative Pharmacology
Head-to-head clinical analysis: ESTRONE versus ETHINYL ESTRADIOL AND NORELGESTROMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRONE versus ETHINYL ESTRADIOL AND NORELGESTROMIN.
ESTRONE vs ETHINYL ESTRADIOL AND NORELGESTROMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Combination contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release via negative feedback on pituitary; progestin (norelgestromin) thickens cervical mucus and inhibits ovulation.
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
One transdermal patch (releasing 0.035 mg ethinyl estradiol and 0.150 mg norelgestromin per 24 hours) applied once weekly for 3 weeks, followed by 1 week patch-free.
None Documented
None Documented
Clinical Note
moderateEstrone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin."
Clinical Note
moderateEstrone sulfate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin."
Clinical Note
moderateEstrone + Rosoxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin."
Clinical Note
moderateEstrone sulfate + Rosoxacin
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Ethinyl estradiol has a terminal elimination half-life of approximately 13-27 hours (mean ~17 hours). Norelgestromin has a terminal half-life of about 28 hours. These half-lives support once-weekly dosing of the transdermal system, achieving steady-state by the second application.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Ethinyl estradiol and norelgestromin are excreted primarily via urine and feces. Ethinyl estradiol undergoes extensive metabolism; about 40% is excreted in urine and 60% in feces as glucuronide and sulfate conjugates. Norelgestromin is metabolized to norgestrel and other metabolites; approximately 45% is excreted in urine and 35% in feces.
Category C
Category D/X
Estrogen
Estrogen
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin."